HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through advanced cardiac insights, announced that it will attend the JP Morgan 2026 Annual Healthcare Conference taking place Jan. 12-15, 2026, at the Westin St. Francis Hotel in San Francisco. Chief Executive Officer Robert Eno and Chief Financial Officer Timothy Cruickshank will be available Jan. 12-14 for off-site meetings with investors and potential commercialization and co-development partners.
Discussions are expected to focus on the company’s recently announced 510(k) clearance from the U.S. Food and Drug Administration for its patented, cable-free 12-lead electrocardiogram synthesis software for arrhythmia assessment, ahead of a planned limited U.S. commercial launch in Q1 2026. This clearance marks a significant milestone for HeartBeam, as it enables the company to bring its innovative technology to the market for non-life-threatening arrhythmia detection.
The HeartBeam System is a portable non-invasive recorder that captures ECG signals in three non-coplanar directions from five electrodes, synthesizing them into a 12-lead ECG representation. The software is intended for manual assessment of normal sinus rhythm and specific non-life-threatening arrhythmias, including sinus arrhythmia, sinus tachycardia, sinus bradycardia, atrial premature complexes, atrial fibrillation, and ventricular premature complex. It is not intended for assessment of other conditions such as myocardial infarction or ventricular arrhythmias.
The company’s attendance at the JP Morgan conference is a strategic opportunity to engage with potential partners and investors as it prepares for commercialization. HeartBeam holds over 20 issued patents related to its technology enablement, and its platform is designed for portable devices that can be used wherever the patient is, delivering actionable heart intelligence outside of medical facilities.
HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-Lead ECG synthesis software received clearance in December 2025. The company is dedicated to transforming the detection and monitoring of critical cardiac conditions, redefining the future of cardiac health management.
For more information about HeartBeam and its technology, visit HeartBeam.com. The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT.
